surmount-1 tirzepatide trial obesity without diabetes ๐ Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but diabetes. Researchers SURMOUNT-MMO: First trial on tirzepatide
Pay in 4 interest-free payments of $5.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Jul 31 - Aug 5

















/sc-assets/prd/practices/de5102cd-f766-4b65-aac0-24f248cbf365/wmremove-transformed%20(2).jpeg)






